Pirfenidone in the treatment of primary sclerosing cholangitis

Paul Angulo, Robert L. MacCarty, Pamela B. Sylvestre, Roberta A. Jorgensen, Russell H. Wiesner, Nicholas F La Russo, Keith D. Lindor

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Our aim was to evaluate the safety and assess the efficacy of pirfenidone, an antifibrotic drug, in patients with primary sclerosing cholangitis (PSC). Twenty-four patients with PSC were enrolled in this pilot study. Oral pirfenidone, 2400 mg daily, was given for one year. Liver biochemistries were determined at three-month intervals. The Mayo risk score was calculated, and liver biopsy and endoscopic cholangiography were performed at entry and at one year of treatment. No signifcant changes in liver biochemistries were noted at the end of the treatment period or at any of the three-month intervals. The Mayo risk score did not change significantly, and no significant changes were noted in the degree of inflammation, fibrosis, histologic stage of disease, or cholangiographic findings at the end of the treatment period. Adverse events occurred in 20/24 (83%) patients, but disappeared shortly after pirfenidone was discontinued. Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC.

Original languageEnglish (US)
Pages (from-to)157-161
Number of pages5
JournalDigestive Diseases and Sciences
Volume47
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Sclerosing Cholangitis
Biochemistry
Liver
Therapeutics
Cholangiography
Fibrosis
pirfenidone
Inflammation
Biopsy
Safety
Pharmaceutical Preparations

Keywords

  • Fibrosis
  • Medical therapy
  • Pirfenidone
  • Primary sclerosing cholangitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Angulo, P., MacCarty, R. L., Sylvestre, P. B., Jorgensen, R. A., Wiesner, R. H., La Russo, N. F., & Lindor, K. D. (2002). Pirfenidone in the treatment of primary sclerosing cholangitis. Digestive Diseases and Sciences, 47(1), 157-161. https://doi.org/10.1023/A:1013240225965

Pirfenidone in the treatment of primary sclerosing cholangitis. / Angulo, Paul; MacCarty, Robert L.; Sylvestre, Pamela B.; Jorgensen, Roberta A.; Wiesner, Russell H.; La Russo, Nicholas F; Lindor, Keith D.

In: Digestive Diseases and Sciences, Vol. 47, No. 1, 2002, p. 157-161.

Research output: Contribution to journalArticle

Angulo, P, MacCarty, RL, Sylvestre, PB, Jorgensen, RA, Wiesner, RH, La Russo, NF & Lindor, KD 2002, 'Pirfenidone in the treatment of primary sclerosing cholangitis', Digestive Diseases and Sciences, vol. 47, no. 1, pp. 157-161. https://doi.org/10.1023/A:1013240225965
Angulo, Paul ; MacCarty, Robert L. ; Sylvestre, Pamela B. ; Jorgensen, Roberta A. ; Wiesner, Russell H. ; La Russo, Nicholas F ; Lindor, Keith D. / Pirfenidone in the treatment of primary sclerosing cholangitis. In: Digestive Diseases and Sciences. 2002 ; Vol. 47, No. 1. pp. 157-161.
@article{828dc12d6577474da0e39491874f4905,
title = "Pirfenidone in the treatment of primary sclerosing cholangitis",
abstract = "Our aim was to evaluate the safety and assess the efficacy of pirfenidone, an antifibrotic drug, in patients with primary sclerosing cholangitis (PSC). Twenty-four patients with PSC were enrolled in this pilot study. Oral pirfenidone, 2400 mg daily, was given for one year. Liver biochemistries were determined at three-month intervals. The Mayo risk score was calculated, and liver biopsy and endoscopic cholangiography were performed at entry and at one year of treatment. No signifcant changes in liver biochemistries were noted at the end of the treatment period or at any of the three-month intervals. The Mayo risk score did not change significantly, and no significant changes were noted in the degree of inflammation, fibrosis, histologic stage of disease, or cholangiographic findings at the end of the treatment period. Adverse events occurred in 20/24 (83{\%}) patients, but disappeared shortly after pirfenidone was discontinued. Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC.",
keywords = "Fibrosis, Medical therapy, Pirfenidone, Primary sclerosing cholangitis",
author = "Paul Angulo and MacCarty, {Robert L.} and Sylvestre, {Pamela B.} and Jorgensen, {Roberta A.} and Wiesner, {Russell H.} and {La Russo}, {Nicholas F} and Lindor, {Keith D.}",
year = "2002",
doi = "10.1023/A:1013240225965",
language = "English (US)",
volume = "47",
pages = "157--161",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Pirfenidone in the treatment of primary sclerosing cholangitis

AU - Angulo, Paul

AU - MacCarty, Robert L.

AU - Sylvestre, Pamela B.

AU - Jorgensen, Roberta A.

AU - Wiesner, Russell H.

AU - La Russo, Nicholas F

AU - Lindor, Keith D.

PY - 2002

Y1 - 2002

N2 - Our aim was to evaluate the safety and assess the efficacy of pirfenidone, an antifibrotic drug, in patients with primary sclerosing cholangitis (PSC). Twenty-four patients with PSC were enrolled in this pilot study. Oral pirfenidone, 2400 mg daily, was given for one year. Liver biochemistries were determined at three-month intervals. The Mayo risk score was calculated, and liver biopsy and endoscopic cholangiography were performed at entry and at one year of treatment. No signifcant changes in liver biochemistries were noted at the end of the treatment period or at any of the three-month intervals. The Mayo risk score did not change significantly, and no significant changes were noted in the degree of inflammation, fibrosis, histologic stage of disease, or cholangiographic findings at the end of the treatment period. Adverse events occurred in 20/24 (83%) patients, but disappeared shortly after pirfenidone was discontinued. Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC.

AB - Our aim was to evaluate the safety and assess the efficacy of pirfenidone, an antifibrotic drug, in patients with primary sclerosing cholangitis (PSC). Twenty-four patients with PSC were enrolled in this pilot study. Oral pirfenidone, 2400 mg daily, was given for one year. Liver biochemistries were determined at three-month intervals. The Mayo risk score was calculated, and liver biopsy and endoscopic cholangiography were performed at entry and at one year of treatment. No signifcant changes in liver biochemistries were noted at the end of the treatment period or at any of the three-month intervals. The Mayo risk score did not change significantly, and no significant changes were noted in the degree of inflammation, fibrosis, histologic stage of disease, or cholangiographic findings at the end of the treatment period. Adverse events occurred in 20/24 (83%) patients, but disappeared shortly after pirfenidone was discontinued. Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC.

KW - Fibrosis

KW - Medical therapy

KW - Pirfenidone

KW - Primary sclerosing cholangitis

UR - http://www.scopus.com/inward/record.url?scp=0036147240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036147240&partnerID=8YFLogxK

U2 - 10.1023/A:1013240225965

DO - 10.1023/A:1013240225965

M3 - Article

C2 - 11837718

AN - SCOPUS:0036147240

VL - 47

SP - 157

EP - 161

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 1

ER -